The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma

Journal of Hypertension

Volumn 28, Issue 9, 2010, Pages 1892-1899

  Rossi, Gian Paolo ^a   Barisa, Marlena ^a   Belfiore, Anna ^a   Desideri, Giovambattista ^a   Ferri, Claudio ^a   Letizia, Claudio ^a   MacCario, Mauro ^a   Morganti, Alberto ^a   Palumbo, Gaetana ^a   Patalano, Anna ^a   Roman, Elisabetta ^a   Seccia, Teresa M ^a   Pessina, Achille C ^a   Mantero, Franco ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

aldosterone; aldosteronism; renin assay; secondary hypertension

Indexed keywords

CAPTOPRIL;

ADENOMA; ADULT; ALDOSTERONE PRODUCING ADENOMA; ARTICLE; ASSAY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIRECT RENIN ASSAY; FEMALE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; IDIOPATHIC DISEASE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCREENING TEST;

EID: 77955850467     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833d2192     Document Type: Article

References (36)

1. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008; 93:2566-2571.
2. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293-2300.
3. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens 2008; 26:613-621.
4. Rossi GP. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue? Curr Hypertens Rep 2004; 6:1-4.
5. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'nonselective' screening of hypertensive patients. J Hypertens 2003; 21:2149-2157.
6. Kaplan NM. Is there an unrecognized epidemic of primary aldosteronism? Con. Hypertension 2007; 50:454-458; discussion 454-458.
7. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension 2007; 50:447-453; discussion 447-453.
8. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16:104-107.
9. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85.
10. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
11. Rossi GP, Rossi E, Pavan E, Rosati N, Zecchel R, Semplicini A, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998; 49:713-723.
12. Rossi GP, Seccia TM, Palumbo G, Belfiore A, Bernini G, Caridi G, et al. Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension 2010; 55:83-89.
13. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902.
14. Anonymous. Idiopathic aldosteronism: a diagnostic artifact? Lancet 1979; 2:1221-1222.
15. Schirpenbach C, Seiler L, Maser-Gluth C, Rudiger F, Nickel C, Beuschlein F, Reincke M. Confirmatory testing in normokalaemic primary aldosteronism: The value of the saline infusion test and urinary aldosterone metabolites. Eur J Endocrinol 2006; 154:865-873.
16. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005; 16:86-91.
17. Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci 2007; 44:1-85.
18. Letavernier E, Peyrard S, Amar L, Zinzindohoue F, Fiquet B, Plouin PF. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2008; 26:1816-1823.
19. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003; 49:7-18.
20. Rossi GP,BolognesiM, RizzoniD, Seccia TM, Piva A,Porteri E,etal. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008; 51:1366-1371.
21. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007; 50:424-431.
22. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, Pessina AC. Identification of the etiology of primary aldosteronism with adrenal vein samplinginpatients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86:1083-1090.
23. Seccia TM, Miotto D, De Toni R, Pitter G, Mantero F, Pessina AC, Rossi GP. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension 2009; 53: 761-766.
24. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48:232-238.
25. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8:135-160.
26. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver operating characteristic analysis for diagnostic tests. Prev Vet Med 2000; 45:23-41.
27. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 2008; 50:419-430.
28. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148:839-843.
29. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008; 19:88-90.
30. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
31. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050.
32. Campbell DJ, Nussberger J, Stowasser M, Danser AH, Morganti A, Frandsen E, Menard J. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009; 55:867-877.
33. Hartman D, Sagnella GA, Chesters CA, Macgregor GA. Direct renin assay and plasma renin activity assay compared. Clin Chem 2004; 50:2159-2161.
34. Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50:1650-1655.
35. Lonati C, Patalano A, De Toni R, Marano G, Morganti A. Direct versus enzymatic renin measurement for the calculation of aldosterone/renin ratio in patients with essential hypertension and with primary aldosteronism. J Hypertens 2009; 27 (Suppl 4):S445.
36. Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005; 46:1069-1076.